All sponsors

Dizal Pharmaceuticals

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS15
PHASE 3 / 2-34
RECRUITING11
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO18%

Delay Index: of 11 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Dizal Pharmaceuticals on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Sunvozertinib
NCT05712902
P2Active, not recruitingNon-Small Cell Lung Cancer1042022-10-17
Sunvozertinib
NCT03974022
P1/2Active, not recruitingNon-Small Cell Lung Cancer3152024-07-29 (+20 mo)
DZD9008 plus Bevacizumab
NCT06276283
P2RecruitingNon-small Cell Lung Cancer602025-12-31 (+7 mo)
sunvozertinib
NCT05668988
P3Active, not recruitingNon-small Cell Lung Cancer3242026-01-16 (-1 mo)
DZD6008
NCT07070440
P1/2RecruitingNon Small Cell Lung Cancer1802027-06
DZD8586 dose level 1
NCT07294365
P2RecruitingImmune Thrombocytopenia (ITP)602027-07
DZD8586
NCT06539182
P2RecruitingChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma1552027-09
Golidocitinib
NCT07234162
P3RecruitingPeripheral T-cell Lymphoma2182027-11-30
DZD6008
NCT07079475
P1/2RecruitingNon-Small Cell Lung Cancer2202028-06 (-6 mo)
GW5282
NCT07328217
P1/2RecruitingAdvanced Solid Tumors2032028-12
DZD8586
NCT07139873
P3RecruitingChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma2502029-01
GW5282 combined with Golidocitinib
NCT07496229
P1/2RecruitingT-cell Lymphomas2202029-09
DZD8586
NCT07154264
P2RecruitingChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma662029-12
DZD8586+R-CHOP
NCT07059650
P1/2RecruitingDiffuse Large B-Cell Lymphoma1502030-10
Birelentinib
NCT07712588
P2/3Not yet recruitingDiffuse Large B-Cell Lymphoma (DLBCL)8802031-01